CeriBell, Inc. (CBLL) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CBLL SEC filings page.
CeriBell, Inc. (CBLL) reported $102.0M in revenue over the twelve months to Jun 30, 2026, up 31.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is scaling, but the operating model still converts growth into losses and cash outflows rather than self-funding expansion.
Revenue rose36.1% from FY2024 to FY2025, yet operating cash flow worsened to-$40.8M . That divergence between growth and cash conversion, alongside continued negative free cash flow despite a wider gross margin, indicates that added activity has not yet translated into internally generated cash.
Gross margin expanded from
FY2024 financing cash flow of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of CeriBell, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
CeriBell, Inc. held $159.3M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $40.8M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and CeriBell, Inc. scores 66/100 among other emerging companies.
CeriBell, Inc. had 38M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and CeriBell, Inc. scores 7/100 among other emerging companies.
CeriBell, Inc. spent $19.1M on research and development in fiscal year 2025, which was 13.0% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and CeriBell, Inc. scores 42/100 among other emerging companies.
CeriBell, Inc. reported revenue of $89.1M in fiscal year 2025, against $65.4M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and CeriBell, Inc. scores 76/100 among other emerging companies.
CeriBell, Inc.'s operations used $40.8M of cash in fiscal year 2025, against $35.0M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and CeriBell, Inc. scores 32/100 among other emerging companies.
CeriBell, Inc.'s cash, cash equivalents and investments came to $159.3M at the end of fiscal year 2025, against $40.5M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and CeriBell, Inc. scores 86/100 among other emerging companies.
CeriBell, Inc. scores 13.80, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.0B) relative to total liabilities ($40.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
CeriBell, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
CeriBell, Inc. reported a net loss of $53.4M while operations used $40.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
CeriBell, Inc. reported an operating loss of $58.4M against $1.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
CeriBell, Inc. generated $28.1M in revenue in Q2 2026. This represents an increase of 32.5% from the same quarter a year earlier. Against the prior quarter it is up 6.1%.
CeriBell, Inc.'s EBITDA was -$19.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 34.1% from the same quarter a year earlier. Against the prior quarter it is up 3.5%.
CeriBell, Inc. reported -$19.3M in net income in Q2 2026. This represents a decrease of 41.2% from the same quarter a year earlier. Against the prior quarter it is up 2.4%.
CeriBell, Inc. earned -$0.51 per diluted share (EPS) in Q2 2026. This represents a decrease of 34.2% from the same quarter a year earlier. Against the prior quarter it is up 1.9%.
Cash & Balance Sheet
CeriBell, Inc. recorded an outflow of $12.9M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 69.4% from the same quarter a year earlier. Against the prior quarter it is up 33.7%.
CeriBell, Inc. held $32.7M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
CeriBell, Inc.'s gross margin was 92.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 4.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.0 percentage points.
CeriBell, Inc.'s operating margin was -71.1% in Q2 2026, reflecting core business profitability. This is down 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.2 percentage points.
CeriBell, Inc.'s net profit margin was -68.6% in Q2 2026, showing the share of revenue converted to profit. This is down 4.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.9 percentage points.
CeriBell, Inc.'s ROE was -15.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 7.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.0 percentage points.
Capital Allocation
CeriBell, Inc. invested $6.7M in research and development in Q2 2026. This represents an increase of 39.1% from the same quarter a year earlier. Against the prior quarter it is up 9.5%.
CeriBell, Inc. invested $17K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 76.1% from the same quarter a year earlier. Against the prior quarter it is down 86.4%.
Not reported for Q2 2026.
CBLL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $28.1M+32.5% | $26.5M+29.3% | $24.8M+33.7% | $22.6M+31.4% | $21.2M+38.4% | $20.5M+42.3% | $18.5M | $17.2M+48.1% |
| Cost of Revenue | $2.2M-14.2% | $3.4M+35.7% | $3.1M+36.8% | $2.6M+21.2% | $2.5M+16.7% | $2.5M+20.7% | $2.3M | $2.2M+15.9% |
| Gross Profit | $25.9M+38.8% | $23.1M+28.4% | $21.6M+33.3% | $19.9M+32.8% | $18.7M+42.0% | $18.0M+45.9% | $16.2M | $15.0M+54.3% |
| R&D Expenses | $6.7M+39.1% | $6.2M+45.1% | $5.1M+29.4% | $5.0M+46.8% | $4.9M+48.4% | $4.2M+42.3% | $3.9M | $3.4M+47.1% |
| SG&A Expenses | $14.8M+29.9% | $15.3M+54.2% | $12.1M+21.6% | $11.0M+22.2% | $11.4M+49.2% | $9.9M+37.3% | $10.0M | $9.0M+80.9% |
| Operating Income | -$20.0M-33.6% | -$20.7M-46.0% | -$14.6M-13.3% | -$14.6M-47.4% | -$15.0M-77.3% | -$14.2M-68.1% | -$12.9M | -$9.9M-38.7% |
| EBITDA | -$19.8M-34.1% | -$20.5M-47.8% | -$14.1M-14.2% | -$14.4M-46.9% | -$14.8M-78.4% | -$13.9M-69.3% | -$12.3M | -$9.8M-39.8% |
| Interest Expense | $438K-8.2% | $434K-7.9% | $462K-7.4% | $480K-9.4% | $477K-9.7% | $471K+8.3% | $499K | $530K-0.4% |
| Income Tax | $0 | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Net Income | -$19.3M-41.2% | -$19.7M-54.5% | -$13.5M-7.6% | -$13.5M-29.3% | -$13.6M-52.6% | -$12.8M-49.9% | -$12.6M | -$10.4M-47.7% |
| EPS (Basic) | -$0.51-34.2% | -$0.52-44.4% | -$0.36-122.1% | -$0.37+80.0% | -$0.38+76.4% | -$0.36+76.9% | $1.63+205.8% | -$1.85-40.2% |
| EPS (Diluted) | -$0.51-34.2% | -$0.52-44.4% | -$0.36-122.1% | -$0.37 | -$0.38 | -$0.36 | $1.63 | -$1.85-40.2% |
| Diluted Shares (Avg) | 38M+4.8% | 38M+5.0% | N/A | 37M | 36M | 36M | N/A | 6M+5.5% |
CBLL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $166.3M-19.9% | $178.1M-16.6% | $195.8M-13.1% | $199.5M+324.0% | $207.7M | $213.5M | $225.4M+282.6% | $47.1M |
| Current Assets | $157.8M-21.0% | $168.9M-17.8% | $186.7M-14.1% | $191.8M+448.6% | $199.8M | $205.4M | $217.3M+318.1% | $35.0M |
| Cash & Equivalents | $32.7M-18.6% | $45.3M-70.5% | $40.5M-79.2% | $23.7M+68.2% | $40.1M+64.8% | $153.4M+372.0% | $194.4M+463.5% | $14.1M-68.9% |
| Short-Term Investments | $96.6M-29.6% | $95.9M+227.0% | $118.8M | $144.8M | $137.3M | $29.3M | $0 | $0 |
| Inventory | $6.7M+12.3% | $6.9M+5.3% | $7.3M+5.1% | $6.0M-12.8% | $6.0M | $6.6M | $6.9M+18.2% | $6.9M |
| Accounts Receivable | $16.0M+29.9% | $15.7M+39.1% | $15.1M+38.4% | $12.2M+22.7% | $12.3M | $11.3M | $10.9M+36.7% | $10.0M |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $38.0M+7.0% | $37.3M+14.3% | $40.5M+18.2% | $35.4M-80.6% | $35.5M | $32.6M | $34.2M-80.0% | $183.0M |
| Current Liabilities | $17.2M+14.6% | $16.2M+36.8% | $19.2M+47.7% | $15.2M+15.9% | $15.0M | $11.8M | $13.0M-39.9% | $13.1M |
| Non-Current Liabilities | $20.8M+1.5% | $21.1M+1.6% | $21.3M+0.1% | $20.3M-10.0% | $20.5M | $20.8M | $21.3M+883.3% | $22.5M |
| Total Equity | $128.3M-25.5% | $140.8M-22.2% | $155.3M-18.7% | $164.1M+220.7% | $172.2M+235.3% | $180.9M+250.9% | $191.2M+270.3% | -$136.0M-29.5% |
| Retained Earnings | -$259.4M-34.1% | -$240.1M-33.6% | -$220.4M-32.0% | -$206.8M-34.0% | -$193.4M | -$179.7M | -$166.9M-32.0% | -$154.4M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
CBLL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$12.9M-70.8% | -$19.3M-69.2% | -$10.8M-8.0% | -$11.1M-29.9% | -$7.5M-8.0% | -$11.4M-19.4% | -$10.0M-49.4% | -$8.5M |
| Depreciation & Amortization | $200K0.0% | $239K-28.7% | $291K-20.1% | $294K+79.3% | $200K+19.8% | $335K+30.4% | $364K+56.2% | $164K-5.2% |
| Stock-Based Compensation | $6.0M+89.4% | $3.7M+58.6% | N/A | $3.3M+143.4% | $3.2M+194.3% | $2.3M+210.2% | N/A | $1.4M+116.0% |
| Capital Expenditures | $17K-76.1% | $125K-15.5% | $179K-49.9% | $369K-34.9% | $71K-77.9% | $148K+55.8% | $357K-25.2% | $567K |
| Free Cash Flow | -$12.9M-69.4% | -$19.4M-68.1% | -$11.0M-6.0% | -$11.5M-25.9% | -$7.6M-4.2% | -$11.6M-19.8% | -$10.3M-44.5% | -$9.1M |
| Investing Cash Flow | -$606K+99.4% | $22.4M+175.8% | $26.1M+5395.7% | -$6.9M-3894.5% | -$107.7M-9215.9% | -$29.6M-22331.1% | -$493K+27.8% | $183K |
| Financing Cash Flow | $880K-56.1% | $1.6M+81500.0% | $1.4M-99.3% | $1.6M+186.9% | $2.0M+100400.0% | $2K-100.0% | $190.7M+5609.2% | -$1.9M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CBLL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.3%+4.2pp | 87.3%-0.6pp | 87.3%-0.3pp | 88.3%+1.0pp | 88.1%+2.2pp | 87.9%+2.2pp | 87.6% | 87.3%+3.5pp |
| Operating Margin | -71.1%-0.6pp | -78.3%-9.0pp | -58.9%+10.6pp | -64.8%-7.1pp | -70.5%-15.5pp | -69.3%-10.6pp | -69.5% | -57.8%+3.9pp |
| Net Margin | -68.6%-4.2pp | -74.5%-12.1pp | -54.6%+13.3pp | -59.6%+1.0pp | -64.4%-6.0pp | -62.4%-3.2pp | -67.8% | -60.6%+0.2pp |
| Return on Equity | -15.0%-7.1pp | -14.0%-7.0pp | -8.7%-2.1pp | -8.2% | -7.9% | -7.1% | -6.6% | N/A |
| Return on Assets | -11.6%-5.0pp | -11.1%-5.1pp | -6.9%-1.3pp | -6.8%+15.4pp | -6.6% | -6.0% | -5.6% | -22.1% |
| Current Ratio | 9.18-4.1x | 10.44-6.9x | 9.73-7.0x | 12.65+10.0x | 13.31 | 17.36 | 16.73+14.3x | 2.67 |
| Debt-to-Equity | 0.30+0.1x | 0.26+0.1x | 0.26+0.1x | 0.22 | 0.21 | 0.18 | 0.18 | N/A |
| Asset Turnover | 0.17+0.1x | 0.15+0.1x | 0.130.0x | 0.11-0.3x | 0.10 | 0.10 | 0.08 | 0.37 |
| FCF Margin | -45.8%-10.0pp | -73.3%-16.9pp | -44.2%+11.6pp | -50.8%+2.2pp | -35.9%+11.8pp | -56.4%+10.6pp | -55.8% | -53.0% |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| CeriBell, Inc. CBLL | FY2025 | $89.1M | -$53.4M | -60.0% | $1.0B | 52/100 |
| Butterfly Network, Inc. BFLY | FY2025 | $97.6M | -$77.1M | -79.0% | $2.3B | 61/100 |
| Semler Scientific, Inc. SMLR | FY2024 | $56.3M | $40.9M | 72.7% | $310.7M | 78/100 |
| RxSight, Inc. RXST | FY2025 | $134.5M | -$39 | 0.0% | $193.8M | 73/100 |
| Treace Medical Concepts, Inc. TMCI | FY2025 | $212.7M | -$59.0M | -27.7% | $266.6M | 45/100 |
| Surmodics, Inc. SRDX | FY2024 | $126.1M | -$11.5M | -9.2% | $614.5M | — |
Where CeriBell, Inc. Ranks
Frequently Asked Questions
What is CeriBell, Inc.'s annual revenue?
CeriBell, Inc. (CBLL) reported $89.1M in total revenue for fiscal year 2025. This represents a 36.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is CeriBell, Inc.'s revenue growing?
CeriBell, Inc. (CBLL) revenue grew by 36.1% year-over-year, from $65.4M to $89.1M in fiscal year 2025.
Is CeriBell, Inc. profitable?
No, CeriBell, Inc. (CBLL) reported a net income of -$53.4M in fiscal year 2025, with a net profit margin of -60.0%.
What is CeriBell, Inc.'s EBITDA?
CeriBell, Inc. (CBLL) had EBITDA of -$57.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is CeriBell, Inc.'s gross margin?
CeriBell, Inc. (CBLL) had a gross margin of 87.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is CeriBell, Inc.'s operating margin?
CeriBell, Inc. (CBLL) had an operating margin of -65.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is CeriBell, Inc.'s net profit margin?
CeriBell, Inc. (CBLL) had a net profit margin of -60.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is CeriBell, Inc.'s return on equity (ROE)?
CeriBell, Inc. (CBLL) has a return on equity of -34.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is CeriBell, Inc.'s free cash flow?
CeriBell, Inc. (CBLL) recorded an outflow of $41.6M in free cash flow during fiscal year 2025. This represents a -14.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is CeriBell, Inc.'s operating cash flow?
CeriBell, Inc. (CBLL) recorded an outflow of $40.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are CeriBell, Inc.'s total assets?
CeriBell, Inc. (CBLL) had $195.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are CeriBell, Inc.'s capital expenditures?
CeriBell, Inc. (CBLL) invested $767K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does CeriBell, Inc. spend on research and development?
CeriBell, Inc. (CBLL) invested $19.1M in research and development during fiscal year 2025.
What is CeriBell, Inc.'s current ratio?
CeriBell, Inc. (CBLL) had a current ratio of 9.73 as of fiscal year 2025, which is generally considered healthy.
What is CeriBell, Inc.'s debt-to-equity ratio?
CeriBell, Inc. (CBLL) had a debt-to-equity ratio of 0.26 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is CeriBell, Inc.'s return on assets (ROA)?
CeriBell, Inc. (CBLL) had a return on assets of -27.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is CeriBell, Inc.'s P/E ratio?
CeriBell, Inc. (CBLL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.0B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is CeriBell, Inc.'s price-to-sales ratio?
CeriBell, Inc. (CBLL) trades at 9.8x sales, its market capitalization divided by revenue of $102.0M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.0B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does CeriBell, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, CeriBell, Inc. (CBLL) held $159.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $40.8M over that year. Dividing the one by the other, the reported balance equals about 47 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is CeriBell, Inc.'s Altman Z-Score?
CeriBell, Inc. (CBLL) has an Altman Z-Score of 13.80, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is CeriBell, Inc.'s Piotroski F-Score?
CeriBell, Inc. (CBLL) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are CeriBell, Inc.'s earnings high quality?
CeriBell, Inc. (CBLL) reported a net loss of $53.4M while operations used $40.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can CeriBell, Inc. cover its interest payments?
CeriBell, Inc. (CBLL) reported an operating loss of $58.4M against $1.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is CeriBell, Inc.?
CeriBell, Inc. (CBLL) scores 52 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.